Maintenance Therapy vs. Supervised Discontinuation
She's eight months into remission from a first depressive episode — inside the guideline window for continuing treatment, but close enough to the edge that stopping now isn't clearly wrong either.
C.V., a 29-year-old marketing coordinator, had her first depressive episode two years ago, triggered in part by a difficult breakup and a demanding job transition, with a peak PHQ-9 of 22 and real functional impairment — missed workdays, withdrawal from friends, several weeks where getting out of bed before noon felt genuinely difficult. Sertraline, started at that time and titrated to 100mg, brought her to full remission by month two, and she has sustained a PHQ-9 of 2-4 for the past eight months without any residual symptoms she or her family can identify.
She has no other chronic illness and no history of depression before this episode, though her mother has had two documented depressive episodes requiring medication in her fifties. C.V. now wants to stop sertraline — not for any acute reason, but because the sexual side effects have been a persistent source of friction in a relatively new relationship, and she has said plainly that she feels like herself again and doesn't want to keep taking a daily medication for a problem that feels resolved.
The guideline literature on continuation treatment generally recommends six to twelve months of maintenance therapy after remission from a first depressive episode before considering a taper, specifically because relapse risk is highest in the months immediately following symptom resolution and drops meaningfully the longer remission is sustained. At eight months, she sits inside that window but close enough to its lower edge that the case for waiting longer is not obviously stronger than the case for tapering carefully now — and her family history adds real uncertainty about her individual recurrence risk that the population-level guideline range doesn't resolve on its own.
At the maintenance-review visit
Her family history is the piece I don't want to discount — a mother with two depressive episodes puts her at meaningfully higher individual recurrence risk than the general population the six-to-twelve-month range was derived from, and I'd lean toward the longer end of that window before tapering rather than the shorter one.
That's a real consideration, but it's also worth naming that the side effect she's describing isn't a minor inconvenience — persistent sexual dysfunction affecting a new relationship is exactly the kind of tolerability problem that predicts covert non-adherence if we simply extend the timeline without addressing it, which would leave her with neither the drug's benefit nor her stated preference honored.
A supervised taper now, done slowly enough to distinguish genuine relapse from discontinuation symptoms, respects both the relapse-risk data and the reason she's actually asking to stop.
I'd add one practical point to the taper plan itself: sertraline's relatively short half-life means discontinuation symptoms — dizziness, brief mood lability, flu-like sensations — are more likely to appear and be mistaken for early relapse than they would be with a longer-acting SSRI. A slow, dose-by-dose taper over eight to ten weeks, with explicit criteria for what counts as relapse versus withdrawal, gives her a real answer instead of leaving her guessing if something comes back in month three.
A structured taper was started, reducing sertraline in defined steps over eight to ten weeks, with explicit written criteria distinguishing expected discontinuation symptoms from early signs of relapse and a scheduled check-in at each dose reduction rather than only at the end.
The medication is stopped entirely, with a clear plan to restart quickly if symptoms reemerge rather than waiting to see how bad it gets first.
Sertraline is restarted at the last effective dose immediately, and the family-history-weighted argument for a longer maintenance period going forward becomes the working plan rather than a deferred consideration.
C.V. left with a written taper schedule and a same-week contact plan for anything that felt ambiguous — the team's explicit goal was making sure she wouldn't have to decide alone, in month three, whether what she was feeling was real.